Table 2. Clinical and biomarker data collected from patients via mLCCare.
| Category | Parameters | Example |
|---|---|---|
| General | Age | |
| Sex | ||
| Hospitalization times | ||
| Diagnosis | Histological type | NSCLC, small cell carcinoma |
| Differentiation | Well, poor | |
| Stage (TNM) | I, IIA, IIB, III, IV | |
| Lymph nodes detected in surgery | ||
| Clinical symptoms | Cough, chest pain, dyspnea, etc. | |
| Others | CT scan, MRI scan, PET scan, etc. | |
| Biopsy | Lymph nodes, hydrothorax, etc. | |
| Biomarker | Biomarker | EGFR mutations, ALK fusion, ROS-1, etc. |
| Treatment | Surgery type | Wedge resection, lobectomy, etc. |
| Chemotherapy (regimen, drug, dosage) | Paclitaxel, cisplatin, docetaxel, pemetrexed, etc. | |
| Target therapy | Gefitinib, Erlotinib, Icotinib, Crizotinib, etc. | |
| Radiotherapy | ||
| Disease progression | Metastasis | Liver, brain, lymph nodes |
| Recurrence | ||
| Treatment outcomes | Response | Partial response, complete response, progress disease, etc. |
| Symptomatic response | Complete disappearance, good improvement, no change, worsening, etc. | |
| Treatment side-effects | Organ-based toxicity | Skin, hair loss, liver, kidney, etc. |
| Bone marrow suppression | ||
| Quality of life | Quality of life | KPS rating (0–100) |
Abbreviations: ALK, anaplastic lymphoma kinase; CT, computed tomography; EGFR, epidermal growth factor receptor; KPS, Karnofsky Performance Status; mLCCare, mobile Lung Cancer Care; NSCLC, non-small cell lung cancer; PET, positron emission tomography; TNM, primary tumor characteristics, nearby lymph node involvement, status of distant metastases.